8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 24, 2026·SEC
Vaxcyte, Inc.(PCVX)Earnings, Financials & Key Ratios
PCVX•NASDAQ
Price updated Jun 19, 2026
AboutVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Show more
- Revenue$0
- EBITDA-$899M-62.3%
- Net Income-$767M-65.2%
- EPS (Diluted)-5.63-48.2%
- ROE-25.59%-25.4%
PCVX Key Insights
Vaxcyte, Inc. (PCVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 53.8% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 11.6% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PCVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PCVX Price & Volume
Vaxcyte, Inc. (PCVX) stock price & volume — 10-year historical chart
Loading chart...
PCVX Growth Metrics
Vaxcyte, Inc. (PCVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-85.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.46%
Return on Capital
10 Years-47.03%
5 Years-33.1%
3 Years-32.11%
Last Year-29.74%
PCVX Recent Earnings
Vaxcyte, Inc. (PCVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$2.30-29.7%
$1.77
Rev
—
$13M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$1.80-17.7%
$1.53
Rev
—
$19M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.56-22.8%
$1.27
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.22-8.9%
$1.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $2.30vs $1.77-29.7% | —vs $13M |
| Q1 2026 | Feb 24, 2026 | $1.80vs $1.53-17.7% | —vs $19M |
| Q4 2025 | Nov 4, 2025 | $1.56vs $1.27-22.8% | — |
| Q3 2025 | Aug 6, 2025 | $1.22vs $1.12-8.9% | — |
Based on last 12 quarters of dataView full earnings history →
PCVX Peer Comparison
Vaxcyte, Inc. (PCVX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 IBRX | 7.71B | 7.36 | -19.37 | 6.68% | -6.06% |
Compare PCVX vs Peers
Vaxcyte, Inc. (PCVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCVX Income Statement
Vaxcyte, Inc. (PCVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 1.04M | 1.23M | 1.41M | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -1.04M▲ 0% | -1.23M▼ 18.8% | -1.41M▼ 14.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | -18.8% | -14.04% | 100% | - | - | - | - | - |
Operating Expenses | 17.4M | 35.53M | 52.92M | 88.18M | 103.67M | 232.26M | 468.04M | 569.55M | 923.67M | 1.09B |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.05M | 5.39M | 7.31M | 14.61M | 25.26M | 39.81M | 60.7M | 92.9M | 129.37M | 129.78M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 12.79M | 30.14M | 45.61M | 73.56M | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M | 958.95M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 5.18M | 0 | 0 | 0 | 23M | 75M | 0 | 0 | 0 |
Operating Income | -17.83M▲ 0% | -35.53M▼ 99.3% | -54.15M▼ 52.4% | -89.58M▼ 65.4% | -103.67M▼ 15.7% | -232.26M▼ 124.0% | -468.04M▼ 101.5% | -569.55M▼ 21.7% | -923.67M▼ 62.2% | -1.09B▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -99.25% | -52.4% | -65.42% | -15.73% | -124.03% | -101.52% | -21.69% | -62.18% | - |
EBITDA | -17.21M | -34.5M | -52.92M | -88.18M | -100.21M | -222.8M | -457.87M | -553.7M | -898.82M | -1.07B |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -100.46% | -53.41% | -66.62% | -13.65% | -122.33% | -105.5% | -20.93% | -62.33% | -72.87% |
D&A (Non-Cash Add-back) | 625K | 1.04M | 1.23M | 1.41M | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M | 19.99M |
EBIT | -17.83M | -29.41M | -50.23M | -89.21M | -100.07M | -223.48M | -402.27M | -463.93M | -766.63M | -625.91M |
Net Interest Income | 0 | 828K | 592K | 237K | 337K | 8.35M | 62.91M | 109.99M | 119.72M | 86.78M |
Interest Income | 164K | 903K | 632K | 244K | 344K | 8.36M | 62.91M | 109.99M | 119.72M | 113.39M |
Interest Expense | 0 | 75K | 40K | 7K | 7K | 2K | 0 | 0 | 0 | 0 |
Other Income/Expense | 595K | 6.05M | 3.88M | 364K | 3.59M | 8.77M | 65.78M | 105.62M | 157.05M | 142.2M |
Pretax Income | -17.24M▲ 0% | -29.48M▼ 71.0% | -50.27M▼ 70.5% | -89.22M▼ 77.5% | -100.08M▼ 12.2% | -223.49M▼ 123.3% | -402.27M▼ 80.0% | -463.93M▼ 15.3% | -766.63M▼ 65.2% | -946.53M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -17.24M▲ 0% | -29.48M▼ 71.0% | -50.27M▼ 70.5% | -89.22M▼ 77.5% | -100.08M▼ 12.2% | -223.49M▼ 123.3% | -402.27M▼ 80.0% | -463.93M▼ 15.3% | -766.63M▼ 65.2% | -946.53M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -71.05% | -70.51% | -77.46% | -12.17% | -123.31% | -80% | -15.33% | -65.25% | -85.73% |
Net Income (Continuing) | -17.24M | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M | -766.63M | -946.53M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.83▲ 0% | -8.12▼ 68.1% | -14.10▼ 73.6% | -2.97▲ 78.9% | -1.93▲ 35.0% | -3.44▼ 78.2% | -4.14▼ 20.3% | -3.80▲ 8.2% | -5.63▼ 48.2% | -6.78▲ 0% |
EPS Growth % | - | -68.12% | -73.65% | 78.94% | 35.02% | -78.24% | -20.35% | 8.21% | -48.16% | -68.46% |
EPS (Basic) | -4.84 | -8.12 | -14.10 | -2.97 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 | - |
Diluted Shares Outstanding | 3.57M | 3.63M | 3.8M | 29.55M | 51.92M | 64.88M | 97.16M | 122M | 136.09M | 139.51M |
Basic Shares Outstanding | 3.56M | 3.63M | 3.79M | 29.55M | 51.92M | 64.88M | 97.16M | 122M | 136.09M | 139.51M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PCVX Balance Sheet
Vaxcyte, Inc. (PCVX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 36.35M | 66.67M | 61.72M | 389M | 256.35M | 942.55M | 1.1B | 1.79B | 1.63B | 1.81B |
Cash & Short-Term Investments | 36.14M | 66.09M | 58.98M | 386.2M | 245.97M | 931.38M | 1.08B | 1.75B | 1.56B | 1.74B |
Cash Only | 36.14M | 66.09M | 58.98M | 386.2M | 68.98M | 834.66M | 397.45M | 387.88M | 173.96M | 260.84M |
Short-Term Investments | 0 | 0 | 0 | 0 | 176.99M | 96.72M | 682.78M | 1.36B | 1.39B | 1.48B |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 3.61M | 20.66M | 46.56M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 5.96M | 20.11M | 2.8M | 76.31M |
Total Non-Current Assets | 3.28M | 4.13M | 3.98M | 3.82M | 67.99M | 63.62M | 311.96M | 1.72B | 1.42B | 1.53B |
Property, Plant & Equipment | 2.97M | 3.41M | 3.39M | 3.27M | 35.91M | 31.65M | 110.62M | 270.15M | 491.72M | 373.8M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 27.12M | 26.55M | 162.68M | 1.39B | 883.13M | 4.01B |
Other Non-Current Assets | 311K | 723K | 584K | 550K | 4.96M | 5.43M | 38.66M | 65.68M | 508K | 157M |
Total Assets | 39.63M▲ 0% | 70.8M▲ 78.7% | 65.7M▼ 7.2% | 392.83M▲ 497.9% | 324.34M▼ 17.4% | 1.01B▲ 210.2% | 1.41B▲ 39.9% | 3.51B▲ 149.4% | 3.05B▼ 13.3% | 3.35B▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 78.65% | -7.21% | 497.93% | -17.43% | 210.23% | 39.93% | 149.4% | -13.25% | 33.32% |
Total Current Liabilities | 4.26M | 6.71M | 11.05M | 46.86M | 28.72M | 40.52M | 145.34M | 140.18M | 205.75M | 242.08M |
Accounts Payable | 1.81M | 2.83M | 3.38M | 29.79M | 6.76M | 9.79M | 14.59M | 48.45M | 70.9M | 63.06M |
Days Payables Outstanding | - | 996.09 | 1K | 7.74K | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.12M | 6.08M |
Deferred Revenue (Current) | 0 | -297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 850K | 2.4M | 433K | 298K | 3.46M | 1.18M | 11.06M | 20.55M | 105.72M | 172.94M |
Current Ratio | 8.53x | 9.93x | 5.58x | 8.30x | 8.93x | 23.26x | 7.54x | 12.75x | 7.91x | 7.49x |
Quick Ratio | 8.53x | 9.93x | 5.58x | 8.30x | 8.93x | 23.26x | 7.54x | 12.75x | 7.91x | 7.49x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.43M | 121.82M | 161.02M | 122K | 11.6M | 12.04M | 22.11M | 65.32M | 154.7M | 110.21M |
Long-Term Debt | 3.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111.36M | 110.21M |
Capital Lease Obligations | 458K | 161K | 0 | 0 | 11.51M | 12.03M | 22.11M | 65.22M | 111.36M | 269.57M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43.25M | 43.25M |
Other Non-Current Liabilities | 212K | 121.66M | 161.02M | 122K | 96K | 9K | 0 | 100K | -111.26M | 0 |
Total Liabilities | 8.69M | 128.53M | 172.07M | 46.98M | 40.32M | 52.56M | 167.45M | 205.5M | 360.45M | 352.29M |
Total Debt | 4.5M | 458K | 161K | 0 | 16.78M | 17.94M | 29.22M | 71.11M | 228.84M | 116.3M |
Net Debt | -31.64M | -65.63M | -58.81M | -386.2M | -52.2M | -816.72M | -368.23M | -316.77M | 54.88M | -144.55M |
Debt / Equity | 0.15x | - | - | - | 0.06x | 0.02x | 0.02x | 0.02x | 0.09x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.14x |
Interest Coverage | - | -392.13x | -1255.85x | -12744.29x | -14295.71x | -111741.50x | - | - | - | - |
Total Equity | 30.94M▲ 0% | -57.73M▼ 286.6% | -106.37M▼ 84.3% | 345.84M▲ 425.1% | 284.02M▼ 17.9% | 953.61M▲ 235.8% | 1.24B▲ 30.1% | 3.31B▲ 166.5% | 2.69B▼ 18.8% | 3B▲ 0% |
Equity Growth % | - | -286.59% | -84.27% | 425.12% | -17.88% | 235.76% | 30.08% | 166.5% | -18.76% | 14.15% |
Book Value per Share | 8.68 | -15.90 | -28.03 | 11.71 | 5.47 | 14.70 | 12.77 | 27.10 | 19.73 | 21.48 |
Total Shareholders' Equity | 30.94M | -57.73M | -106.37M | 345.84M | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B | 3B |
Common Stock | 6K | 6K | 7K | 54K | 56K | 82K | 98K | 128K | 134K | 147K |
Retained Earnings | -29.59M | -59.07M | -109.35M | -198.56M | -298.64M | -522.13M | -924.39M | -1.39B | -2.15B | -2.48B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -1.75M | 0 | 0 | -241K | -361K | 179K | -3.87M | 1.59M | -6.83M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PCVX Cash Flow Statement
Vaxcyte, Inc. (PCVX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.96K | -30.47M | -47.15M | -46.63M | -121.39M | -170.6M | -296.79M | -452.63M | -655.58M | -769.93M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -203508.9% | -54.75% | 1.1% | -160.34% | -40.53% | -73.97% | -52.51% | -44.84% | -306.46% |
Net Income | -17.24K | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M | -766.63M | -946.53M |
Depreciation & Amortization | 625 | 1.04M | 1.23M | 1.41M | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M | 25.84M |
Stock-Based Compensation | 390 | 749K | 1.19M | 5.43M | 10.73M | 23.65M | 48.76M | 84.82M | 138.84M | 108.23M |
Deferred Taxes | 0 | 51K | 0 | 301K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 260 | -4.71M | -3.2M | 179K | 1.5M | 7.05M | -34.77M | -34.47M | -72.56M | -23.98M |
Working Capital Changes | 1K | 1.9M | 3.91M | 35.27M | -37.01M | 12.74M | 81.32M | -54.9M | 19.91M | 66.51M |
Change in Receivables | 0 | 1.27M | 868K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | -1.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 1.27M | 868K | 26.1M | -12.47M | 2.9M | 11.22M | 34.58M | 19.91M | 48.8M |
Cash from Investing | -1.12K | -1.77M | -1.2M | -1.1M | -212.31M | 74.58M | -773.31M | -2.01B | 437.35M | 80.63M |
Capital Expenditures | -1.22K | -1.77M | -1.2M | -1.16M | -6.55M | -5.84M | -67.88M | -22.43M | -13.71M | -1.76M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 1K | 0 | 50K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 106 | 1K | 0 | 0 | 26K | 0 | 0 | -96.73M | -43.26M | -43.26M |
Cash from Financing | 43.86K | 62.19M | 41.57M | 374.87M | 17.8M | 861.55M | 639.81M | 2.45B | 2.01M | 602.84M |
Debt Issued (Net) | -188K | -283K | -278K | -61K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 62.34M | 42.5M | 373.89M | 13.9M | 856.48M | 636.04M | 2.44B | 0 | 610.88M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 231.86K | 128K | -655K | 1.04M | 3.9M | 5.07M | 3.77M | 12.85M | 2.01M | -8.04M |
Net Change in Cash | 27.78K▲ 0% | 29.95M▲ 107715.0% | -7.11M▼ 123.8% | 327.22M▲ 4699.7% | -316.34M▼ 196.7% | 765.67M▲ 342.0% | -436.97M▼ 157.1% | -9.36M▲ 97.9% | -213.77M▼ 2184.1% | -85.86M▲ 0% |
Free Cash Flow | -16.18K▲ 0% | -32.24M▼ 199096.8% | -48.34M▼ 49.9% | -47.78M▲ 1.2% | -127.95M▼ 167.8% | -176.44M▼ 37.9% | -364.67M▼ 106.7% | -475.05M▼ 30.3% | -669.29M▼ 40.9% | -771.68M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -199096.79% | -49.94% | 1.15% | -167.77% | -37.9% | -106.68% | -30.27% | -40.89% | -28.61% |
FCF per Share | -0.00 | -8.88 | -12.74 | -1.62 | -2.46 | -2.72 | -3.75 | -3.89 | -4.92 | -5.53 |
FCF Conversion (FCF/Net Income) | 0.00x | 1.03x | 0.94x | 0.52x | 1.21x | 0.76x | 0.74x | 0.98x | 0.86x | 0.82x |
Interest Paid | 0 | 0 | 40K | 0 | 7K | 2K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PCVX Key Ratios
Vaxcyte, Inc. (PCVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -74.51% | -31.78% | -36.12% | -36.67% | -20.41% | -25.59% | -32.51% |
Return on Invested Capital (ROIC) | - | - | - | -81.22% | -94.49% | -69.57% | -22.13% | -24.18% | -29.32% |
Debt / Equity | - | - | - | 0.06x | 0.02x | 0.02x | 0.02x | 0.09x | 0.04x |
Interest Coverage | -392.13x | -1255.85x | -12744.29x | -14295.71x | -111741.50x | - | - | - | - |
FCF Conversion | 1.03x | 0.94x | 0.52x | 1.21x | 0.76x | 0.74x | 0.98x | 0.86x | 0.82x |
Related:PCVX Dividend History·PCVX Revenue History·PCVX Price History·PCVX P/E History·PCVX Financial Ratios·PCVX Institutional Holders
PCVX SEC Filings & Documents
Vaxcyte, Inc. (PCVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PCVX Frequently Asked Questions
Vaxcyte, Inc. (PCVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vaxcyte, Inc. (PCVX) grew revenue by 0.0% over the past year. Growth has been modest.
Vaxcyte, Inc. (PCVX) reported a net loss of $946.5M for fiscal year 2025.
Dividend & Returns
Vaxcyte, Inc. (PCVX) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.
Vaxcyte, Inc. (PCVX) had negative free cash flow of $771.7M in fiscal year 2025, likely due to heavy capital investments.